Compare Elder Pharma with IPCA Labs - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs IPCA LABS - Comparison Results

IPCA LABS 
   Change

Ipca Laboratories is an integrated pharmaceutical company with presence in intermediates, APIs and formulations. The company has a strong focus on exports, catering to the US, Europe and the semi-regulated markets of the CIS, Africa and Asia. The com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA IPCA LABS ELDER PHARMA/
IPCA LABS
 
P/E (TTM) x -0.2 25.2 - View Chart
P/BV x 0.1 7.9 1.3% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 ELDER PHARMA   IPCA LABS
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
IPCA LABS
Mar-19
ELDER PHARMA/
IPCA LABS
5-Yr Chart
Click to enlarge
High Rs3801,042 36.5%   
Low Rs188590 31.9%   
Sales per share (Unadj.) Rs491.2298.6 164.5%  
Earnings per share (Unadj.) Rs-3.235.0 -9.1%  
Cash flow per share (Unadj.) Rs14.449.4 29.1%  
Dividends per share (Unadj.) Rs03.00 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs376.5247.1 152.4%  
Shares outstanding (eoy) m20.54126.35 16.3%   
Bonus/Rights/Conversions -ESOS-  
Price / Sales ratio x0.62.7 21.2%   
Avg P/E ratio x-89.323.3 -382.8%  
P/CF ratio (eoy) x19.716.5 119.4%  
Price / Book Value ratio x0.83.3 22.8%  
Dividend payout %08.6 0.0%   
Avg Mkt Cap Rs m5,833103,108 5.7%   
No. of employees `000NA13.4 0.0%   
Total wages/salary Rs m2,1797,874 27.7%   
Avg. sales/employee Rs ThNM2,807.0-  
Avg. wages/employee Rs ThNM585.8-  
Avg. net profit/employee Rs ThNM329.0-  
INCOME DATA
Net Sales Rs m10,08937,732 26.7%  
Other income Rs m257577 44.5%   
Total revenues Rs m10,34638,309 27.0%   
Gross profit Rs m-7926,901 -11.5%  
Depreciation Rs m3611,824 19.8%   
Interest Rs m2,756189 1,460.7%   
Profit before tax Rs m-3,6535,465 -66.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1251,042 12.0%   
Profit after tax Rs m-654,422 -1.5%  
Gross profit margin %-7.818.3 -42.9%  
Effective tax rate %-3.419.1 -18.0%   
Net profit margin %-0.611.7 -5.5%  
BALANCE SHEET DATA
Current assets Rs m9,24023,778 38.9%   
Current liabilities Rs m9,99810,975 91.1%   
Net working cap to sales %-7.533.9 -22.1%  
Current ratio x0.92.2 42.7%  
Inventory Days Days46104 44.6%  
Debtors Days Days6066 90.9%  
Net fixed assets Rs m10,12420,368 49.7%   
Share capital Rs m206253 81.4%   
"Free" reserves Rs m5,58230,971 18.0%   
Net worth Rs m7,73431,224 24.8%   
Long term debt Rs m4,8891,409 347.1%   
Total assets Rs m22,88245,507 50.3%  
Interest coverage x-0.330.0 -1.1%   
Debt to equity ratio x0.60 1,401.4%  
Sales to assets ratio x0.40.8 53.2%   
Return on assets %11.810.1 116.1%  
Return on equity %-0.814.2 -6.0%  
Return on capital %22.317.3 128.8%  
Exports to sales %3.045.9 6.6%   
Imports to sales %0.416.6 2.6%   
Exports (fob) Rs m30717,308 1.8%   
Imports (cif) Rs m436,266 0.7%   
Fx inflow Rs m30717,308 1.8%   
Fx outflow Rs m1256,266 2.0%   
Net fx Rs m18111,042 1.6%   
CASH FLOW
From Operations Rs m11,7544,923 238.8%  
From Investments Rs m-561-1,563 35.9%  
From Financial Activity Rs m-6,762-1,832 369.1%  
Net Cashflow Rs m4,4321,528 290.1%  

Share Holding

Indian Promoters % 39.6 45.9 86.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.4 65.8%  
FIIs % 16.8 25.3 66.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.4 207.5%  
Shareholders   16,479 36,892 44.7%  
Pledged promoter(s) holding % 77.6 2.1 3,624.3%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   GSK PHARMA  JUBILANT LIFE SCIENCES  BIOCON   PIRAMAL ENTERPRISES  NATCO PHARMA  

Compare ELDER PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

5 Reasons Why Sensex and Nifty Plunged 2% Today(Closing)

Indian share markets witnessed heavy selling pressure today despite the US administration saying it would bring a stimulus package even without the opposition's support.

Related Views on News

IPCA LABS Announces Quarterly Results (1QFY21); Net Profit Up 243.5% (Quarterly Result Update)

Sep 29, 2020 | Updated on Sep 29, 2020

For the quarter ended June 2020, IPCA LABS has posted a net profit of Rs 5 bn (up 243.5% YoY). Sales on the other hand came in at Rs 15 bn (up 46.9% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (3QFY20); Net Profit Up 22.8% (Quarterly Result Update)

Feb 17, 2020 | Updated on Feb 17, 2020

For the quarter ended December 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 22.8% YoY). Sales on the other hand came in at Rs 11 bn (up 20.2% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (2QFY20); Net Profit Up 63.7% (Quarterly Result Update)

Nov 12, 2019 | Updated on Nov 12, 2019

For the quarter ended September 2019, IPCA LABS has posted a net profit of Rs 2 bn (up 63.7% YoY). Sales on the other hand came in at Rs 12 bn (up 21.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (1QFY20); Net Profit Up 101.5% (Quarterly Result Update)

Aug 27, 2019 | Updated on Aug 27, 2019

For the quarter ended June 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 101.5% YoY). Sales on the other hand came in at Rs 10 bn (up 18.4% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

IPCA LABS Announces Quarterly Results (4QFY19); Net Profit Up 113.4% (Quarterly Result Update)

Jun 3, 2019 | Updated on Jun 3, 2019

For the quarter ended March 2019, IPCA LABS has posted a net profit of Rs 1 bn (up 113.4% YoY). Sales on the other hand came in at Rs 8 bn (up 6.5% YoY). Read on for a complete analysis of IPCA LABS's quarterly results.

More Views on News

Most Popular

Time to Book Profits in Pharma Stocks(Fast Profits Daily)

Jan 15, 2021

In this video, I'll show you why it might be the right time to take money of the table in pharma stocks.

Smallcap Stocks: Your Best Bet for 2021 and Beyond(Profit Hunter)

Jan 15, 2021

The pandemic failed to thwart Richa's investing success formula for 2020.

One Chart to See Before You Sell(Fast Profits Daily)

Jan 22, 2021

In this video, I'll show you a crucial chart that you need to check before you decide to sell any stock or index.

Invest in the Multibaggers of 2021 and Beyond(Profit Hunter)

Jan 21, 2021

Our ace stock picker is ready to capitalise on a big growth opportunity.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS